Literature DB >> 23999004

Antitumor activity of histamine and clozapine in a mouse experimental model of human melanoma.

Noelia A Massari1, Vanina A Medina, Graciela P Cricco, Diego J Martinel Lamas, Lorena Sambuco, Romina Pagotto, Clara Ventura, Pablo J Ciraolo, Omar Pignataro, Rosa M Bergoc, Elena S Rivera.   

Abstract

BACKGROUND: Functional presence of histamine H4 receptor (H4R) was demonstrated in human melanoma cell lines and biopsies.
OBJECTIVE: The purposes of this work were to investigate signal transduction pathways and biological responses triggered by the activation of H4R in human primary (WM35) and metastatic (M1/15) melanoma cell lines and to evaluate the in vivo antitumor activity of histamine (HA) and clozapine (CLZ) on human M1/15 melanoma xenografts.
METHODS: Clonogenic assay, incorporation of BrdU, cell cycle distribution, phosphorylation levels of ERK1/2 and cAMP production were evaluated in vitro. An experimental human melanoma model was developed into athymic nude mice. Tumor growth, survival and histochemical studies were performed in order to investigate the expression levels of H4R, HA, PCNA, mitotic index (MI), and angiogenesis.
RESULTS: The results indicate that H4R agonists inhibited forskolin-induced cAMP levels only in M1/15 cells while increased phosphorylation levels of ERK1/2 and decreased proliferation in both cell types. In vivo studies show that HA and CLZ (1mgkg(-1), sc) significantly increased median survival and decreased tumor volume. These effects were associated to a reduction in MI, in the expression of proliferation marker and in intratumoral neovascularization.
CONCLUSIONS: We conclude that HA and CLZ exhibit an antitumoral effect in vitro and in vivo on human melanoma, suggesting the therapeutic potential of these compounds for the treatment of malignant melanoma.
Copyright © 2013 Japanese Society for Investigative Dermatology. Published by Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  ERK1/2; H(4)R; Histamine; Melanoma; Proliferation; Survival

Mesh:

Substances:

Year:  2013        PMID: 23999004     DOI: 10.1016/j.jdermsci.2013.07.012

Source DB:  PubMed          Journal:  J Dermatol Sci        ISSN: 0923-1811            Impact factor:   4.563


  14 in total

Review 1.  Histamine receptors and cancer pharmacology: an update.

Authors:  Noelia A Massari; Melisa B Nicoud; Vanina A Medina
Journal:  Br J Pharmacol       Date:  2018-12-13       Impact factor: 8.739

2.  Synthesis and evaluation of antitumor activity of dibenzodiazepine derivatives.

Authors:  Ke Cao; Jianwei Yan; Fulin Yan; Tiantian Yin
Journal:  Mol Divers       Date:  2020-02-19       Impact factor: 2.943

3.  1H NMR Metabolomics Study of Metastatic Melanoma in C57BL/6J Mouse Spleen.

Authors:  Xuan Wang; Mary Hu; Ju Feng; Maili Liu; Jian Zhi Hu
Journal:  Metabolomics       Date:  2014-12       Impact factor: 4.290

Review 4.  International Union of Basic and Clinical Pharmacology. XCVIII. Histamine Receptors.

Authors:  Pertti Panula; Paul L Chazot; Marlon Cowart; Ralf Gutzmer; Rob Leurs; Wai L S Liu; Holger Stark; Robin L Thurmond; Helmut L Haas
Journal:  Pharmacol Rev       Date:  2015-07       Impact factor: 25.468

5.  Integrated Drug Expression Analysis for leukemia: an integrated in silico and in vivo approach to drug discovery.

Authors:  M H Ung; C-H Sun; C-W Weng; C-C Huang; C-C Lin; C-C Liu; C Cheng
Journal:  Pharmacogenomics J       Date:  2016-03-15       Impact factor: 3.550

6.  Selective cytoprotective effect of histamine on doxorubicin-induced hepatic and cardiac toxicity in animal models.

Authors:  D J Martinel Lamas; M B Nicoud; H A Sterle; E Carabajal; F Tesan; J C Perazzo; G A Cremaschi; E S Rivera; V A Medina
Journal:  Cell Death Discov       Date:  2015-12-21

7.  Histamine therapeutic efficacy in metastatic melanoma: Role of histamine H4 receptor agonists and opportunity for combination with radiation.

Authors:  Noelia A Massari; Melisa B Nicoud; Lorena Sambuco; Graciela P Cricco; Diego J Martinel Lamas; María V Herrero Ducloux; Horacio Blanco; Elena S Rivera; Vanina A Medina
Journal:  Oncotarget       Date:  2017-04-18

8.  microRNA-33a-5p increases radiosensitivity by inhibiting glycolysis in melanoma.

Authors:  Ke Cao; Jingjing Li; Jia Chen; Li Qian; Aijun Wang; Xiang Chen; Wei Xiong; Jintian Tang; Shijie Tang; Yong Chen; Yao Chen; Yan Cheng; Jianda Zhou
Journal:  Oncotarget       Date:  2017-07-05

9.  Pathophysiological Role of Histamine H4 Receptor in Cancer: Therapeutic Implications.

Authors:  Melisa B Nicoud; Karina Formoso; Vanina A Medina
Journal:  Front Pharmacol       Date:  2019-06-05       Impact factor: 5.810

10.  Differential expression of neurogenes among breast cancer subtypes identifies high risk patients.

Authors:  Patricia Fernández-Nogueira; Paloma Bragado; Vanessa Almendro; Elisabet Ametller; Jose Rios; Sibgat Choudhury; Mario Mancino; Pedro Gascón
Journal:  Oncotarget       Date:  2016-02-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.